PT - JOURNAL ARTICLE AU - Yasushi Tsujimoto AU - Yuki Kataoka AU - Masahiro Banno AU - Shunsuke Taito AU - Masayo Kokubo AU - Yuko Masuzawa AU - Yoshiko Yamamoto TI - Gestational diabetes mellitus in women born small or premature: Systematic review and meta-analysis AID - 10.1101/2021.06.29.21259746 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.29.21259746 4099 - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259746.short 4100 - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259746.full AB - Background Women born preterm or with low birthweight (LBW) have an increased future risk of gestational diabetes mellitus (GDM) during pregnancy; however, a quantitative summary of evidence is lacking.In this study, we aimed to investigate whether being born preterm, or with LBW or small for gestational age (SGA) are associated with GDM risk.Methods We searched the MEDLINE, Embase, and CINAHL databases and study registries, including ClinicalTrials.gov and ICTRP, from launch until 29 October 2020 for observational studies examining the association between birth weight or gestational age and GDM were eligible. We pooled the odds ratios and 95% confidence intervals using the DerSimonian and Laird random-effects model.Results Eighteen studies were included (N = 827,382). The meta-analysis showed that being born preterm, with LBW or SGA was associated with increased risk of GDM (pooled odds ratio = 1.84; 95% confidence interval: 1.54 to 2.20; I2 = 78.3%; τ2 = 0.07). Given a GDM prevalence of 2.0%, 10%, and 20%, the absolute risk differences were 1.6%, 7.0%, and 11.5%, respectively. The certainty of evidence was low due to serious concerns of risk of bias and publication bias.Conclusion Women born prematurely, with LBW or SGA status, may be at increased risk for GDM. However, whether this should be considered in clinical decision-making depends on the prevalence of GDM.What is already known on this subject?Approximately 10–15% of infants are born small or premature worldwide, and these children are at high risk of diseases, such as type 1 and 2 diabetes mellitus, hypertension, obesity, and kidney disease, in adulthood. A narrative review reported in 2007 that women born with LBW are at risk of gestational diabetes mellitus, but included a small number of studies. Several subsequent studies have been published since then, but there is no quantitative summary of the relevant evidence to date.What this study adds?This is the first systematic review and meta-analysis of observational studies that provides a comprehensive summary of evidence on the association between birth size or premature birth and future GDM risk including previously unpublished data and a large sample size. LBW, preterm birth, and SGA status may be prognostic factors for GDM.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialPROSPERO (CRD42020142004)Funding StatementThe English editing fee was supported by the Systematic Review Peer Support Group (not for profit organisation). The funders played no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was not required for this systematic review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.